Envista (NVST)
(Delayed Data from NYSE)
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.70 USD
-0.14 (-0.78%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $17.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth B Momentum B VGM
Zacks News
NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio
by Zacks Equity Research
NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.
Align Technology (ALGN) Launches Professional Whitening System
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities
by Zacks Equity Research
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
Here's Why You Should Invest in Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
LHC Group (LHCG) to Boost Nationwide Presence With New Buyout
by Zacks Equity Research
LHC Group's (LHCG) deal win enables the company to acquire home health, hospice and therapy assets in 22 states.
Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes
by Zacks Equity Research
Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.
Omnicell (OMCL) New Buyout Expands Patient Engagement Suite
by Zacks Equity Research
With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.
NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone
by Zacks Equity Research
NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
by Zacks Equity Research
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
7 Low Price-to-Book Stocks to Buy in September
by Kinjel Shah
The P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Syneos Health (SYNH) Enhances Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
by Zacks Equity Research
Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
SmileDirectClub (SDC) Struggles With New Markets, High Debt
by Zacks Equity Research
SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.
ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy
by Zacks Equity Research
A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients
Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System
by Zacks Equity Research
Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academia, biopharma and contract research organizations.